Monica Cejuela - Publications

Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 05, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Clinical features and management for CDK4/6 inhibitor-DILI.

Journal: JHEP reports : innovation in hepatology

Published: January 29, 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: November 24, 2025

RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now? Int. J. Mol. Sci. 2022, 23, 2705.

Journal: International journal of molecular sciences

Published: May 23, 2025

Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.

Journal: Therapeutic advances in medical oncology

Published: August 12, 2024

Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.

Journal: Scientific reports

Published: June 15, 2024

Targeting the Tumor Microenvironment in Breast Cancer: Prognostic and Predictive Significance and Therapeutic Opportunities.

Journal: International journal of molecular sciences

Published: October 25, 2023

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.

Journal: International journal of molecular sciences

Published: April 04, 2023

Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.

Journal: Current oncology reports

Published: September 26, 2022

RETRACTED: Metformin and Breast Cancer: Where Are We Now?

Journal: International journal of molecular sciences

Published: January 30, 2022